New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
All of the free stories from today.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | all day >>
07:35 EDTMXIMMaxim Integrated downgraded at MKM Partners
As previously reported, MKM Partners downgraded Maxim Integrated to Neutral from Buy. The firm downgraded shares citing limited demand catalysts for Mobility and lack of diversification. Price target is $30.
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
08:55 EDTThe FCC Consumer Advisory Committee to hold a meeting
Subscribe for More Information
07:34 EDTCPLPCapital Product reports Q2 EPS 4c, consensus 10c
Reports Q2 revenue $47.44M, consensus $49.31M.
07:34 EDTNUENucor 'confident' in future favorable rulings for steel industry, Reuters says
Subscribe for More Information
07:33 EDTIMAXIMAX shares attractive at current levels, says JPMorgan
Subscribe for More Information
07:33 EDTLMLegg Mason acquisition positive, says Wells Fargo
After Legg Mason agreed to buy international equity manager Martin Currie, Wells Fargo thinks the deal will enable Legg Mason to gain a foothold in international equity, while enabling Currie to leverage Legg Mason's retail distribution channel. The firm does not expect the deal to affect Legg Mason's share buybacks. It keeps an Outperform rating on the shares.
07:33 EDTAGNEMA recommends expanded indication for Ozurdex
Subscribe for More Information
07:32 EDTABT, ABAX, BAYRY, HSKA, IDXX, MWIV, NEOGAmerican Veterinary Medical Association to hold a conference
Subscribe for More Information
07:32 EDTLOCOCorrection: El Pollo Loco 7.142M share IPO priced at $15.00
The deal range was $13.00-$15.00 range. Jefferies, Morgan Stanley and RW Baird acted as joint book running managers for the offering.
07:31 EDTABBVEMA recommends expanded indication for Humira
Subscribe for More Information
07:30 EDTNVONovo Nordisk receives positive opinion from CHMP
Subscribe for More Information
07:30 EDTDSCIDerma Sciences sees sales of Medihoney dressings approaching $20M in 2014
07:29 EDTOSTKOverstock.com upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
07:29 EDTEarnings keep averages at elevated levels
Subscribe for More Information
07:29 EDTPFEEMA recommends indication for Ecalta to treat invasive candidiasis
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Ecalta, offered by Pfizer. The CHMP adopted a change to an indication as follows: "Treatment of invasive candidiasis in adult patients."
07:27 EDTBMYEMA recommends expanded indication for Baraclude
Subscribe for More Information
07:26 EDTOECOrion Engineered Carbons 19.5M share IPO priced at $18.00
Subscribe for More Information
07:25 EDTGILDGilead receives positive opinion from CHMP for Zydelig
Gilead Sciences announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig, a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular lymphoma, the most common subtype of indolent non-Hodgkin lymphoma. The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy or, as first-line treatment in CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy and also as monotherapy for the treatment of adult patients with FL that is refractory to two prior lines of treatment. The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union. The CHMP positive opinion for Zydelig is based on data from two clinical trials – Study 116 and Study 101-09. Study 116, a pivotal Phase 3 trial, investigated the efficacy and safety of Zydelig in combination with rituximab in patients with previously treated CLL. The Phase 2 101-09 study assessed the efficacy and safety of Zydelig in patients with iNHL who are refractory to rituximab and alkylating agents. Results of Study 116 and Study 101-09 were published in The New England Journal of Medicine in March 2014.
07:24 EDTDNKNDunkin' Brands price target lowered to $46-$48 from $53-$55 at Wells Fargo
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use